In a world grappling with increasing polarization and global challenges, Kate Robertson, co-founder of One Young World, is championing a unique vision. She envisions a future where G20 leaders are not just politicians but also ambassadors of One Young World, a global forum dedicated to empowering young leaders. Co-founded by Robertson in 2009, One Young […]
Anavex Life Sciences has announced encouraging findings from the long-term extension of its Phase 2 study evaluating ANAVEX®2-73 in patients with Parkinson’s disease dementia. The 48-week open-label extension study has demonstrated that ANAVEX®2-73 not only met but exceeded its primary and secondary objectives. The study, ANAVEX2-73-PDD-EP-001, aimed to assess the safety, tolerability, and efficacy of […]
Kate Robertson, the co-founder of One Young World, envisions a transformative shift in global leadership. Her goal is to see G20 leaders not just as politicians, but as ambassadors who have emerged from One Young World, a forum renowned for empowering young leaders worldwide. In a recent statement, Kate Robertson emphasized the urgent need for […]
Ella Robertson, nmanaging director of One Young World, recently shared her perspectives on the evolving landscape of global youth leadership. As a leading figure in the organization, Ella Robertson’s insights are instrumental in shaping how future leaders understand and tackle the world’s pressing issues. One Young World, a prominent global forum for young leaders, has […]
Anavex Life Sciences recently announced promising results from a 48-week Phase 2 extension study evaluating their lead drug candidate, ANAVEX®2-73, for Parkinson’s disease dementia. The study successfully met both its primary and secondary objectives, indicating potential efficacy in managing this debilitating condition. In the course of the study, ANAVEX®2-73 exhibited a favorable safety profile and […]